FENC Fennec Pharma: רווח למניה ב-12 החודשים האחרונים

Fennec Pharmaceuticals (FENC) specializes in developing agents that prevent chemotherapy-induced hearing loss. The business relies on high macro-resilience and a lack of seasonality due to strict medical protocols and insurance. Massive scaling potential allows a single successful development to fully offset R&D costs. The current EPS is 112.90. The price action on this chart underscores the dominance of the PEDMARK drug in the pediatric niche and a steady influx of new clinics.

Investors are assessing the stability of Fennec Pharmaceuticals (FENC) through the business's ability to generate sustainable cash flow. This indicator measures the percentage change in net income per share over the last twelve months relative to the same period last year. By analyzing the EPS YoY TTM growth rate, one can determine the commercialization efficiency of the drug Pedmark within pediatric protocols. Positive momentum confirms the monetization of a unique hearing protection niche and the fundamental resilience of the company.